Thursday, June 27, 2019
News
NEWS HOME
»
PRN INDIA
Merck Data at ASCO 2019 Showcase Multiple Innovative Molecules with Potential to Impact Unmet Needs in Cancer Care
  SocialTwist Tell-a-Friend  
   

DARMSTADT, Germany, May 15, 2019 /PRNewswire/ --    

Not intended for UK- , Canada- or US-based media

ASCO Abstract #
Bintrafusp alfa (bifunctional fusion protein):
TPS9114; Tepotinib (MET kinase inhibitor): 9005; Discovery: 2567; ERBITUX ® (cetuximab): 3580; BAVENCIO ® (avelumab): 9569; 101; 4552; 4072

  • New biomarker analyses for BAVENCIO ®* (avelumab) in combination with axitinib in first-line renal cell carcinoma (RCC)
  • Data presented across several modalities and mechanisms showcase the scientific innovation and diversity of the company's pipeline, which includes bintrafusp alfa‡ (M7824) and tepotinib†

Merck, a leading science and technology company, today announced that data across several modalities and mechanisms targeting difficult-to-treat cancers will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4, Chicago, IL, US. New data will be presented for BAVENCIO ®* (avelumab)  and ERBITUX ® (cetuximab), including rational combinations with chemotherapy, radiation therapy and other targeted agents to try to identify new ways to improve patient outcomes. This includes an oral presentation of data defining biomarkers that differentiate therapy-specific outcomes in patients with advanced renal cell carcinoma (RCC), and who have been treated first-line with BAVENCIO ®  (avelumab) in combination with axitinib. Abstracts also showcase the scientific innovation and diversity of Merck's pipeline, with results from a number of high-priority clinical development programs, including tepotinib†, bintrafusp alfa‡  (M7824) and the company's comprehensive DNA Damage Response (DDR) portfolio.

"At this year's ASCO meeting we continue to demonstrate the breadth and depth of our oncology and immuno-oncology portfolio. We will present examples of the latest precision medicine and biomarker research and some of the most exciting mechanisms being investigated today, including tepotinib and our first-in-class bifunctional fusion protein immunotherapy, bintrafusp alfa," said Luciano Rossetti, Global Head of Research & Development for the Biopharma business of Merck. "Merck's oncology pipeline has significant promise in the near term through our late-stage priority programs, and our early pipeline includes several potentially groundbreaking modalities. We look forward to sharing the latest science with the global oncology community."

For BAVENCIO ® (avelumab), Merck will share data from five studies across tumor types including Merkel cell carcinoma, RCC, hepatocellular carcinoma and urothelial carcinoma. This includes an oral presentation of biomarker analyses of baseline tumor samples from the Phase III JAVELIN Renal 101 trial in previously untreated patients with advanced RCC. The trial indicated that PD-L1 expression (≥1% immune cells) was associated with the longest progression-free survival (PFS) in the avelumab plus axitinib arm and the shortest PFS in the sunitinib arm (HR, 0.63; 95% CI, 0.49, 0.81). An analysis of relevant gene expression signatures (GES) indicated that in the avelumab plus axitinib arm, PFS was enhanced in immune GES–positive patients vs those in the negative group (HR, 0.63; 95% CI, 0.46, 0.86; 2-sided p=0.004), and vs those in an independent dataset (JAVELIN Renal 100; Choueiri, Lancet Oncol, 2018) (HR, 0.46; 95% CI, 0.20, 1.05; 2-sided p=0.064). The combination demonstrated a safety and tolerability profile consistent with the known safety profiles of each drug alone. The most common adverse reactions (≥20%) were diarrhea, fatigue, hypertension, musculoskeletal pain, nausea, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, rash, hepatotoxicity, cough, dyspnea, abdominal pain, and headache. Serious adverse reactions occurred in 35% of patients receiving BAVENCIO ® (avelumab) in combination with axitinib. The incidence of major adverse cardiovascular events (MACE) was higher with BAVENCIO ® (avelumab) in combination with axitinib vs sunitinib.

ERBITUX ® (cetuximab) data from a retrospective analysis of overall survival by subsequent therapy in patients with RAS wild-type metastatic colorectal cancer from the Phase III EPIC study will be presented, to evaluate the effect of post-study therapies (with ERBITUX ®, without ERBITUX ®, or no subsequent therapy) on OS.

A number of the molecules to be featured were discovered in-house at Merck. This includes tepotinib, an oral MET inhibitor designed to inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations, and bintrafusp alfa, a bifunctional fusion protein designed to simultaneously target two immuno-suppressive pathways. Merck's partnership with GSK to jointly develop and commercialize bintrafusp alfa, announced in February 2019, is part of the company's strategic approach to oncology R&D. Together, Merck and GSK aim to rapidly and efficiently progress this molecule, which represents a potential step change in the treatment of cancer.

For tepotinib, promising updated results from the ongoing Phase II VISION study in 85 patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations (identified by liquid biopsy [LBx] or tumor biopsy [TBx]) will be shared. Results show an overall response rate (ORR) of 51.4% for LBx patients (independent review committee [IRC]-assessed) or 63.9% (investigator-assessed). The ORR for TBx patients was 41.5% (IRC-assessed) or 58.5% (investigator-assessed). Median duration of response was 9.8 (IRC-assessed) or 17.1 months (investigator-assessed) for LBx patients and 12.4 (IRC-assessed) or 14.3 months (investigator-assessed) for TBx patients. Any grade treatment-related adverse events (TRAEs) reported by ≥10% of 69 patients evaluable for safety were peripheral edema (47.8%), diarrhea (18.8%), nausea (15.9%) and asthenia (10.1%). No Grade 4 or 5 TRAEs were observed. TRAEs led to permanent discontinuation in two (2.9%) patients (one interstitial lung disease, one diarrhea and nausea). These data continue to mature, and an updated data cut from the VISION study will be given as an oral presentation at the ASCO meeting on Monday, June 3.

For bintrafusp alfa, a trial-in-progress poster will be shared on the open-label study of bintrafusp alfa vs pembrolizumab as a first-line treatment in patients with PD-L1-expressing advanced NSCLC.

Merck takes a personalized approach to R&D, and precision medicine has long been a priority. Abstracts being presented at ASCO also include biomarker research programs that aim to help identify the patients most likely to benefit from specific treatments so they can achieve the best possible medical outcomes.

*The combination of BAVENCIO and axitinib is approved for the first-line treatment of advanced RCC only in the United States. There is no guarantee that avelumab in combination with axitinib  will be approved for RCC by any other health authority worldwide.

†Tepotinib is the recommended International Nonproprietary Name (INN) for the MET kinase inhibitor (MSC2156119J). Tepotinib is currently under clinical investigation and not approved for any use anywhere in the world.

‡Bintrafusp alfa is the proposed International Nonproprietary Name (INN) for the bifunctional immunotherapy M7824. Bintrafusp alfa is currently under clinical investigation and not approved for any use anywhere in the world.

Notes to Editors

Key Merck-supported abstracts slated for presentation are listed below. In addition, a number of investigator-sponsored studies have been accepted (not listed).

Title

Lead Author

Abstract #

Presentation
Date / Time
(
CDT)

Location

BAVENCIO ® (avelumab)





Oral Session





Biomarker analyses from
JAVELIN Renal 101:
avelumab + axitinib
(A+Ax) vs sunitinib (S)
in advanced renal cell
carcinoma (aRCC)

T.K. Choueiri

101

Sat, Jun 1, 8:00
AM – 9:30 AM
(8:12 AM – 8:24
AM lecture time)

Hall D1

Poster Sessions

5-factor prognostic
model for survival of
patients with metastatic
urothelial carcinoma
receiving 3 different
post-platinum PD-L1
inhibitors

G. Sonpavde

4552

Mon, Jun 3, 1:15
PM – 4:15 PM

Hall A

First-line avelumab +
axitinib in patients with
advanced hepatocellular
carcinoma: results from
a phase 1b trial (VEGF
Liver 100)

M. Kudo

4072

Mon, Jun 3, 8:00
AM – 11:00 AM

Hall A

Integrative molecular
analysis of metastatic
Merkel cell carcinoma to
identify predictive
biomarkers of response
to avelumab

S. Georges

9569

Mon, Jun 3, 1:15
PM – 4:15 PM

Hall A

Bintrafusp Alfa

Poster Session

Randomized open-label
study of M7824 vs
pembrolizumab as first-
line (1L) treatment in
patients with PD-L1
expressing advanced
non-small cell lung
cancer (NSCLC)

L. Paz-Ares

TPS9114

Sun, Jun 2, 8:00
AM – 11:00 AM

Hall A

Discovery

Poster Session

Understanding
contribution and
independence of multiple
biomarkers for
predicting response to
atezolizumab

P.K. Shah

2567

Sat, Jun 1, 8:00
AM – 11:00 AM

Hall A

ERBITUX ® (cetuximab)

Poster Session





Retrospective Analysis of
Overall Survival (OS) by
Subsequent Therapy in
Patients With RAS-Wild-
type (wt) Metastatic
Colorectal Cancer
(mCRC) Receiving
Cetuximab ± Irinotecan  

A. Sobrero

3580

Mon, Jun 3, 8:00
AM – 11:00 AM

Hall A

Tepotinib

Oral Session

Phase II study of
tepotinib in
NSCLC  patients with
METex14 mutations

P.K. Paik

9005

Mon, Jun 3, 8:00 AM –
11:00 AM (9:24
AM – 9:36 AM
lecture time)

Hall B1

 

About Tepotinib

Tepotinib, discovered in-house at Merck, is an investigational oral MET inhibitor that is designed to inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations, including both MET exon 14 skipping mutations and MET amplifications, or MET protein overexpression. It has been designed to have a highly selective mechanism of action, with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations.

Tepotinib is currently being investigated in NSCLC and Merck is actively assessing the potential of investigating tepotinib in combination with novel therapies and other tumor indications.

About Bintrafusp Alfa (M7824)

Bintrafusp alfa is an investigational bifunctional immunotherapy that is designed to combine a TGF-β trap with the anti-PD-L1 mechanism in one fusion protein. Bintrafusp alfa is designed to combine co-localized blocking of the two immuno-suppressive pathways – targeting both pathways aims to control tumor growth by potentially restoring and enhancing anti-tumor responses. Bintrafusp alfa is currently in Phase I studies for solid tumors, as well as a randomized  Phase II trial to investigate bintrafusp alfa compared with pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced NSCLC. The multicenter, randomized, open-label, controlled study is evaluating the safety and efficacy of bintrafusp alfa versus pembrolizumab as a monotherapy treatment.

To date, nearly 700 patients have been treated with bintrafusp alfa across more than 10 tumor types in Phase I studies. Encouraging data from the ongoing Phase I studies indicates bintrafusp alfa's potential safety and clinical anti-tumor activity across multiple types of difficult-to-treat cancers, including advanced NSCLC, human papillomavirus-associated cancers, biliary tract cancer and gastric cancer. In addition, in pre-clinical studies bintrafusp alfa demonstrated superior anti-tumor activity, compared with anti-PD-L1 alone or with anti-PD-L1 and TGF-β trap when co-administered. In total, eight high-priority immuno-oncology clinical development studies are ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers.

About BAVENCIO ® (avelumab)

BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.1-3 BAVENCIO has also been shown to induce NK cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.3-5 In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO.

The clinical development program for avelumab, known as JAVELIN, involves at least 30 clinical programs and about 10,000 patients evaluated across more than 15 different tumor types. These tumor types include RCC, gastric/gastro-esophageal junction cancer, head and neck cancer, Merkel cell carcinoma, non-small cell lung cancer, and urothelial carcinoma.

BAVENCIO approved Indications

In September 2017, the European Commission granted conditional marketing authorization for BAVENCIO as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). BAVENCIO is currently approved for patients with MCC in more than 45 countries globally, with the majority of these approvals in a broad indication that is not limited to a specific line of treatment.

BAVENCIO ® (avelumab) in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of (i) adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC) and (ii) patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12  months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. These indications are approved under accelerated approval based on tumor response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

BAVENCIO ® Safety Profile from the EU Summary of Product Characteristics (SmPC)

The special warnings and precautions for use for BAVENCIO include infusion-related reactions and immune-related adverse reactions (such as pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and renal dysfunction, and other adverse reactions).

The SmPC list of the most common adverse reactions in patients with solid tumors includes fatigue, nausea, diarrhea, decreased appetite, constipation, infusion-related reactions, and weight loss and vomiting.

Axitinib Important Safety Information from the US FDA Approved Label

In the study of advanced RCC after failure of one prior systemic therapy, the warnings and precautions for axitinib include hypertension, including hypertensive crisis, arterial and venous thrombotic events, hemorrhagic events, cardiac failure, gastrointestinal perforation and fistula, hypothyroidism, wound healing complications, reversible posterior leukoencephalopathy syndrome (RPLS), proteinuria, liver enzyme elevation, hepatic impairment, and fetal harm during pregnancy.

Common adverse events (reported in at least 20% of patients) in patients receiving axitinib were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, weight decreased, vomiting, asthenia, and constipation.

About ERBITUX ® (cetuximab)

Erbitux ® is an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux ® is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Based on in vitro evidence, Erbitux ® also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody-dependent cell-mediated cytotoxicity [ADCC]).

Very commonly reported side effects with Erbitux ®  include acne-like skin rash, mild to moderate infusion-related reactions and hypomagnesemia.

Erbitux ® has already obtained market authorization in 114 countries worldwide for the treatment of RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck. Merck licensed the right to market Erbitux ®, a registered trademark of ImClone LLC, outside the U.S. and Canada from ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company, in 1998.

References

  1. Dolan DE, et al. Cancer Control 2014;21:231–7.
  2. Dahan R, et al. Cancer Cell 2015;28:285–95.
  3. Boyerinas B, et al. Cancer Immunol Res 2015;3:1148–57.
  4. Kohrt HE, et al. Immunotherapy 2012;4:511–27.
  5. Hamilton G, et al. Expert Opin Biol Ther 2017;17:515–23.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to  www.merckgroup.com/subscribe  to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Your Contact
Brenda.Mulligan@merckgroup.com  
Phone: +1 978 821 5345

Logo: https://mma.prnewswire.com/media/886350/Merck_logo.jpg

 

Merck (PRNewsfoto/Merck)

 

 

More News by PR Newswire India

Japanese Whisky Company Scoops International Awards, Makes Waves in Whisky World

Compuware Advances Cross-Platform CI/CD with Machine Learning, Expanded Git Integration and Customized Expert Services

Dr Anunaya Chaubey Joins Anant National University as its New Provost

Fractal Analytics Named a Leader Among Customer Analytics Service Providers by an Independent Research Firm

PPE Degree: Toolkit for Tomorrow's Leaders

Nanjing Jiangbei New Area launches "source place plan"

Alliance Ventures Invests in the Mobility House to Boost Electric Mobility

Ryan International School, Greater Noida Awarded 'Leading Schools of India'

Transportation CRM Software From MovingNow: Processes for Profitability

METRON Raises an Additional €10 Million of New Capital

A Slice of Heritage in Modernity at jĂĽSTa Sajjangarh

Manipal's AUA College of Medicine's Graduates of 2019 Set to Add to the Global Physician Workforce

Sodexo Partners With Rebel Foods to Bring Delicious Meals to 3 Million Consumers

McGraw-Hill Collaboration with Renaissance eServices Will Bring Online Medical Education Courses to Thousands of Students, Professionals in India

Warburg Pincus Closes $4.25 Billion China-Southeast Asia II Fund

Artprice: The "Toulouse Caravaggio" Acquired Privately!

NPCC Abu Dhabi Celebrates Completion of One of the World's Largest Offshore Oil Platforms for ADNOC

EdgeVerve Launches AssistEdge Engage to Redefine Contact Center Experience

Royal Canadian Mint issues coin minted of pure Nunavut gold in celebration of the 20th Anniversary of Canada's newest territory

Asia's Best-in-Class Companies Celebrated at the 2019 Frost & Sullivan Asia-Pacific Best Practices Awards

Modern Take on Traditional Weddings at The Jehan

Suning.com Ranked 1st Place Among China's Most Valuable Brand in Retail Industry

Corteva Completes Board of Directors with Appointment of Marcos Lutz

Corteva Announces $1 Billion Share Repurchase Program and Quarterly Dividend

Affle International Pte. Ltd. Acquires the Platform and Business Assets of RevX Inc.

Global PADI Women's Dive Day Events Give Back to Our Blue Planet

FreightBro Signs MoU With The National Association of Freight and Logistics, Dubai

Saudi Aramco Advances Global Chemicals Strategy With S-Oil Expansion Project in Ulsan, South Korea

Saudi Aramco Signs 12 Agreements With South Korean Partners Worth Billions of Dollars

Transcend Water Launches to Offer Revolutionary Automated Design Software for the Global Water Sector

HGC announces IPX peering arrangement with Telia Carrier

Purecircle Holdings Announces Name Change to Pure CE

Qualcomm and ZTE to Advance 5G Cloud Gaming on Live Networks

Swiss Re Brings a Shine Through Social Entrepreneurs

Pradip Burman, Chairman Mobius Foundation Launched Project 'AAKAR' Phase 2 to Promote Population Stabilization

Innoviti Uses ML-based Path Predictor Technology to Dramatically Improve User Experience of Google Pay Payments on POS Terminals at Physical Stores

NetLinkz announces China revenue from China Telecom Wuxi Pilot

UST Global Honored With Stevie Awards® for 'Human Resources Team of the Year'

Xoxoday Strengthens it's Leadership Team With Ten New Hires

42Gears Launches Things Management Technology to Manage 'Connected' Devices

Seoul National University, KAIST and POSTECH top Reuters fourth annual ranking of Asia Pacific's Most Innovative Universities

BTS WORLD Is Available Worldwide On iOS And Android Devices Starting Today

RM Sotheby's And Formula 1® Present Michael Schumacher's Championship-Winning Ferrari F2002 In Abu Dhabi

The Royal Canadian Mint Releases Innovative Tributes to Canada Just in Time for Annual July 1st Celebrations

Cinemo Acclaimed by Frost & Sullivan for its Modular and Feature-rich In-vehicle Infotainment Systems

Amit Bhadhana’s Latest Video School Ka Last Day is Pure Delight for Fans

TEMSA Signs 46.5 Million Euro Deal in Romania

Palantir Earns Acclaim from Frost & Sullivan for Its Unified Data Platform, Palantir Foundry

League Earns Acclaim from Frost & Sullivan for its End-to-end Platform that Delivers a Personalized Health Benefits Experience

The Royal Canadian Mint and United States Mint Team up to Launch Joint Pride of Two Nations Coin Set

Dynata Launches New Marketplace to Revolutionize Access to First-Party Consumer Data

HighJump Transforms Supply Chain for Mexico's GAIA

Avalon University School of Medicine granted ACCM accreditation

IoT Opportunities in Mexico: Identify Verticals to Invest in by 2022

Waves Breaks into dApps Market Launching Smart Contracts Functionality

Supermicro Introduces Industry's First Server & Storage Systems Supporting EDSFF - First Compact Open Industry Standard for All-Flash NVMe Optimized Storage

Hyperloop Transportation Technologies Provides USDOT with Exclusive First-Look at Full-Scale System and Presents Certification Guidelines

New 'Digital Consumer Intelligence' Industry To Evolve Market Research

Diebold Nixdorf Unveils Next-Generation Banking Solutions Built For The Transforming Financial Services Industry

Seagram's Imperial Red Rum Presented With 'Gold Quality Award' at Monde Selection 2019

Walmart China Takes on Food Safety with VeChainThor Blockchain Technology

ECi Software Solutions Applauded by Frost & Sullivan for its SMB-centric Suite of ERP Solutions

Leading Environmental NGOs Stand Together to Call for 100% Observer Coverage on Industrial Tuna Fishing Vessels

DevOps Institute Advances the Human Elements of DevOps with SKIL Framework

Underprivileged Kids of Thane Find a New Ray of Hope Through Grand Maratha Foundation and Yuva Sena

Corteva Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corporation

Weight Reduction Urgency Creates Dynamic Product and Technology Innovations in the Automotive Composites Sector

Nucleus Software's Latest Version of FinnOne Neo to Help Lenders Accelerate Their Path to Digital Revenues

Store and Exhibition Alliance: CIFF Shanghai 2019 Partners With Retailers to Offer 1.2 Million Square Meter Exhibition Space

The First Annual G20 Data Scorecard Report Highlights the Research Performance of the World's Leading Economies

NetLinkz Ltd (ASX: NET) announces Successful Lab Testing of Cyber Security SDWAN VIN Software with US Federal Government IT Solutions Provider Blue Tech

ZTE secures 25 5G commercial contracts

SucSEED Backs i2iFunding Second Time, India's Leading Online NBFC - Peer to Peer (P2P) Lending Platform

Lightyear Unveils the World's First Long-range Solar Car

Zinnov Says the Media & Entertainment Market, Currently Pegged at USD 1.7 Tn, Will Grow to Touch USD 2.4 Tn by 2023

87% of IT Decision Makers Plan to Increase Their Analytics Workforce in the Next One Year

MindCraft Partners With Automation Anywhere to Propel RPA in the Financial Services Industry

ZTE to demonstrate its all-around preparation for end-to-end 5G commercial use at MWC Shanghai 2019

Phoenix Shopping Festival: Get ready to indulge in Phenomenal Sale, Fascinating events, and Fantastic fun

MSB (Erstwhile Maritime Bank) Elevates Customer Experience With SunTec Xelerate®

Kitchen Brains® appoints Anna Brechoteau Director of IoT Enterprise Solutions

2019 World Industrial and Energy Internet Expo held in E. China's Changzhou

SAMI Acquires Riyadh-based Advanced Electronics Company (AEC)

Medtech Nears its Golden Age Focusing on Value-based Care

Margaret Franklin, CFA, Appointed CEO and President of CFA Institute

Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres

UBM India Announces the SAFE South India and OSH South India Exhibitions in Hyderabad

Tethr and Red Box Announce Partnership to Accelerate and Simplify the Delivery of Voice of Customer Analytics Solution

HGC launches new API hub to further advance digital transformation

ANAROCK Partners With Aldar to Market its Abu Dhabi Properties in India

SutraHR Launches India’s 1st HR Toolkit - StartupHR Toolkit

IIT Faculty Join Hands to Give Students Top Ranks at Giraffe Learning

Admissions Open at IDeA Design College

TiE Mumbai and Dubai International Financial Centre (DIFC) Help Indian FinTechs Scale Their Business Across Middle East, Africa and South Asia Region

Glenmark to Partner With Novartis to Promote, Commercialize and Distribute Three Respiratory Products in Brazil

From Smart Washing to the Future of Clothing and Fabric Care: Haier Unveils Its Latest 2019 Innovations to Enrich Its Internet of Clothes Capacity

INTL FCStone Opens IT Development Services Office in Bangalore, India

"Forging a new energy future" - iCEP Presents AOGC

Suning.com announces the acquisition of Carrefour China to achieve leaping development of FMCG retailing operations

CECEP Solar Energy Technology Unveils Cost-Effective PV Products and Solutions at SNEC 2019

Sebastián Yatra Premieres New Single "RUNAWAY," In Collaboration With Jonas Brothers, Daddy Yankee, And Natti Natasha

MEIL's Worlds Biggest Pumphouse Inaugurated

Asia’s Premier Wedding and Event Photography & Film Making Festival by Capturing WOW

Casablanca and Toronto Forge Closer Links to Foster Global Financial Services Collaboration

Hunt for Indian K-pop Stars Begin for Z-POP DREAM Season 2

Social Kinnect Evolves its Brand Identity to Kinnect

Immerge Knowledge Labs Launches India’s First End-to-End Emerging Tech and XR Business Consulting Firm

YANNI will Perform at the Prambanan Jazz Festival 2019 on July 6th

"All Night," Third Song From BTS WORLD's Original Soundtrack, To Be Released On June 21

JNA Awards reveals 2019 Honourees

Merck's Massachusetts-based Business Sectors Named 'Best Places to Work' by Boston Business Journal

Giift Launches CoolfenPay, a Fully Integrated Points Payment Gateway

SPIE To Acquire Photonex, UK's Top Photonics Exhibition

Universal Fibers Expands Finished Yarn Capabilities in Europe and Asia

Artprice: France's Cultural Policy is Not in the Country's Best Interests According to thierry Ehrmann

Instart Becomes The First Cloud-Based Security Service To Deliver Complete Web App and API Protection

The Web of Science Group Releases 2019 Journal Citation Reports, Revealing the World's Most Influential Journals

Grand Slam Tennis Champion, Naomi Osaka, Named Newest bareMinerals Global Ambassador

Navitas Earns 2019 Global Technology Innovation Award for GaNFast™ Power ICs

Organica Water Awarded Monumental Project in India

Definiens & Targos Innovation: AI-powered multiplex IHC biomarker analytic solutions for precision medicine

Early Detection Cancer Camp Organized by Shree Ramkrishna Knowledge Foundation at Lathi Taluka in Amreli

Avon appoints HCL Technologies as IT infrastructure Services Partner to Support ongoing Digital Transformation

Mohit Bharatiya, who Introduced India to Gold Lending Rates and Gold Spot Exchange, Steps Down From the Jewellery and Bullion Body

founderINDIA Launches Business Class - a Chat Show With Leading Entrepreneurs

Giftalove.com Launches Online Service of Same-day Flower Delivery Nationwide

Suning's Tax-free Subsidiary Laox Announced a Fundraising of 10.1 Billion Japanese Yen to Expand China Business and Global E-commerce

REEL Strengthens Board of Directors and Senior Leadership Team With New Appointments to Support Next Phase of Growth

PwC Launches Solution Supporting Audit of Cryptocurrency

EB5 Capital Visits India to Raise Investment for New York Ritz-Carlton Project as the Hotel Chain Comes to Pune and Mumbai for the First Time

Aeroflot Expands Route Network for Summer 2019

Flexible Workspace Cements its Place as Mainstream Real Estate Asset Class; Significant M&A Activity Forecast in 2019 as Sector Consolidates: Colliers International India

Diversity and Inclusion Still at a Nascent Stage in India, Says a JobsForHer Report on Gender Diversity

Glenmark Pharmaceuticals Receives Tentative ANDA Approval for Clindamycin Phosphate Foam, 1%

Mango Hotels Launches 46 Key Boutique Hotel in Haridwar

Versa Networks Achieves NSS Labs Recommended Rating in the 2019 SD-WAN Group Test with its Security-Enabled SD-WAN

First-ever successful mind-controlled robotic arm without brain implants

Learn How to Map Your Organization's Journey to Customer Satisfaction and Success

HONOR Kicks off HONOR 20 Global Availability, Continues Record-breaking Sales Performance in China

Global Premiere of Renault TRIBER in India

LG U+ Selects iBwave as the Tool of Choice to Bring Asia's First 5G Stadium Design

Engine Restoration Begins on One-of-a-Kind Ferrari Boat

Waystar's Uniquely Agile Ambulatory RCM Solution for Automating Claims Resolution Acclaimed by Frost & Sullivan

Employees Rate Enterprise's Pam Nicholson as Top CEO for Fourth Year in a Row

Siklu Delivers Public Safety and Public Wifi for the City of Cambridge, Ontario Canada

UNSW's India Open Day Returns for a Promising 2nd Innings

Retraining and Retaining: The effect of Automation

Arms Race Driving Investment in C4ISR, Missile Defense Systems, and Network-Centric Warfare Models

EdgeVerve Product TradeEdge Receives POI Best-in-Class Award for Distributor Management

EuroKids Franchise Orientation and Awards Night - Bringing Together the Partners for a Celebration

JD Institute is now Certified as 'Global League Institute' at the House of Commons by Great Place to Study Research Institute

MEIL Constructs the Largest Lift Irrigation Marvel: KLIP Ready for Inauguration

Data Analytics Outsourcing Market in India is Worth $27 Billion: Study by AIM & Praxis Business School

Kitchen Brains® appoints Dave Jendal Vice President, Global Business Solutions

QS World University Rankings 2020: MIT Top, US Universities Hit Historic Low

Increase in Interest for EB-5 in India - EB-5 India Reaches its per Country Limit in July, 2019

Capsave Finance Pvt Ltd. posts net profits in second year of operations

Libyan Sovereign Wealth Fund Refused Permission to Appeal

Frost & Sullivan Global Survey Outlines the Next Wave of Technology Disruptors

Aeroflot Named Best Airline in Eastern Europe for Eighth Time at Skytrax World Airline Awards 2019

Arria NLG and UiPath push digital transformation and automation forward with new strategic partnership

Piramal Pharma Solutions recognized by Frost & Sullivan for its End-to-End Integrated Services Across the Entire Drug Development Life Cycle

Cendyn announces strategic follow on equity investment from Accel-KKR

Brickwork Finance Academy Proudly Conferred the Seventh Convocation and Announced the Eighth Inaugural of its Banking and Financial Analyst Certification Program

Publicis Sapient Announces John Maeda as Chief Experience Officer

Art of the Wild Comes to Life in Paris at the Extravagant Launch of HyperNature, an Event by Perrier-Jouët

Hatsun Agro Product Ltd – Update on Start of Cattle Feed Production in Maharashtra and Expansion of Company Retail Outlets

SubAir Could be a Solution to the Wet Outfields of the Cricket World Cup

US Army deploys Howler counter-UAS capability into the battlefield

LyondellBasell and Neste announce commercial-scale production of bio-based plastic from renewable materials

Casio has Inducted a Market Sweep Action in Kolkata

Global 3D Print Materials Market for Healthcare Industry Set for Quantum Change and 20.3% CAGR Growth from 2018 to 2025

The Republic of Ecuador Announces the Results of Its Invitation for Offers to Tender for Cash Its 2020 Notes

Amazon India Emerges as the Country's Most Attractive Employer Brand Followed by Microsoft India: Randstad Employer Brand Research 2019

ColorTokens Takes Zero Trust Security to a New-generation by Unifying Network and Endpoint Security Into a Single, Cloud-delivered Platform

Companies with a strong travel culture have a competitive advantage: New research from Harvard Business Review Analytic Services in association with Egencia

Thomas Wittek Appointed as R. STAHL India MD and Board Member

RateGain Acquires BCV to Help Hotel Chains Maximize Guest Lifetime Value

Wise MPay Partners With Jelurida to Launch Blockchain Financial Services Platform in Southeast Asia

India's SME-focused Digital Neo Bank EZOTO Gearing up for Launch in June 2019

Aiozium Launched SaaS-based Marketing Intelligence Tool Powered by AI

TV18 Broadcast India Upgrades its Newsgathering Operations with Over 100 LiveU LU600 HEVC Units

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Modi targets Congress on NRC...
Punjab, narcotics bureau to conduct raid...
Print works of Mexican engraver on view ...
Chopping mangroves for Bullet Train dang...
Congress opposes diability pension tax o...
Modi attacks Congress, seeks Opposition ...
More...    
 
 Top Stories
Afghan President Ghani arrives in P... 
Patient sues Google, University of ... 
UP government to reimburse Atal's a... 
'Pakistan are back in this World cu... 
Woman gang-raped by brothers-in-law... 
'Deepfakes' videos different from f... 
We must sue Facebook, Google: Trump... 
IAF's Jaguar suffers bird hit, land...